Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s):  BIOAF

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.


TSXV:BTI.H - Post by User

Post by JDavenporton Jun 20, 2022 5:34pm
312 Views
Post# 34769800

The Plan

The PlanI've heard enough stuff for now. It's obvious that this is a play to move Bioasis into a larger arena. It looks like you're all going to make money. The Cresence people took the stock. Is that their play or is there a bigger win for them? The BIG Vancouver Broker who claims control of 90% of Bioasis stock seems happy with the plans that he seems to know and nobody else knows. Talk to him, not me.

xB3-001 appeared by mistake at the D&P Show, further proof of carelessness in investor relations. So, who was actually meant to see that xB3-001 information and why? 

A full Cresence/EGF1 update of the website and corporate presentation should have been completed before the PR and then their posting to the Bioasis website triggered by the PR. Wasn't done! Are there secrets that can't be revealed yet?

Rollback of 30 to 1 is what I heard, or at least what a couple of people claim to have understood in conversations. A hundred million shares down to 3 million? Wow! What then? An IPO that dilutes current shareholders to nothing? Another IR fiasco!

Meanwhile, the readers of this forum are on their own. There is now way that anybody can offer a legitimate opinion, pro or con, about the current state and future plans for Bioasis.

Usually we would say, follow the money. In this case, the money to follow is expressed in shares, and rollback of shares and new owners, likely new Cresence board members, and liquidity events, and Nasdaq and another partner or two and Ladenburg Thalmann and who knows what.

The message out of Bioasis is a mess. Look for more information when the Q1 report comes out at the end of July, or after a half dozen press releases come out over the summer, or after the AGM so that you'll be voting without the information that others have and aren't sharing.

I have nothing to say about it all for now.

jd
<< Previous
Bullboard Posts
Next >>